Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Olaparib + Pembrolizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Olaparib | Lynparza | AZD2281|KU-0059436 | PARP Inhibitor (Pan) 31 | Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, in combination with abiraterone in patients with mCRPC harboring deleterious or suspected deleterious BRCA mutations, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov). |
Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, PMBL, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous SCC, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-positive NSCLC, esophageal SCC, cervical cancer, and TNBC, in combination with platnum-based chemo in NSCLC, with pemetrexed and platinum in pleural mesothelioma and non-sNSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in sNSCLC, with axitinib or lenvatinib in RCC, with lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemo for esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemo for CD274 (PD-L1)-positive, HER2-positive gastric or GEJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemo for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-positive (CPS>=1) cervical cancer, in combination with gemcitabine and cisplatin for biliary tract cancer, in combination with chemoradiation for cervical cancer, and in combination with carboplatin and paclitaxel for endometrial carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04643379 | Phase II | Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT06116578 | Phase II | Pembrolizumab Olaparib + Pembrolizumab | Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc) | Not yet recruiting | FRA | 0 |
NCT03834519 | Phase III | Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) | Completed | USA | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 5 |
NCT04666740 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | Active, not recruiting | USA | 0 |
NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Active, not recruiting | USA | 0 |
NCT04753879 | Phase II | Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Recruiting | USA | 0 |
NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT04825990 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT) | Recruiting | ITA | 0 |
NCT05524935 | Phase II | Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | Recruiting | USA | 0 |
NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | TUR | ROU | POL | NOR | LVA | LTU | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | ARG | 9 |
NCT04306367 | Phase II | Olaparib + Pembrolizumab | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Active, not recruiting | USA | 0 |
NCT05623319 | Phase II | Cisplatin + Etoposide + Pembrolizumab Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR) | Recruiting | ITA | 0 |
NCT04633902 | Phase II | Olaparib + Pembrolizumab | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | Recruiting | USA | 0 |
NCT03025035 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | Recruiting | USA | 0 |
NCT05379972 | Phase II | Olaparib + Pembrolizumab | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | Recruiting | USA | 0 |
NCT03976323 | Phase III | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | Active, not recruiting | USA | TUR | ROU | POL | NZL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 6 |
NCT05268510 | Phase II | Olaparib + Pembrolizumab Capecitabine + Oxaliplatin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma | Active, not recruiting | DEU | 0 |
NCT04483544 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab and Olaparib in Cervical Cancer Patients | Active, not recruiting | USA | 0 |
NCT05203445 | Phase II | Olaparib + Pembrolizumab | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT02861573 | Phase I | Dexamethasone + Docetaxel + Pembrolizumab + Prednisone Olaparib + Pembrolizumab Enzalutamide + Pembrolizumab | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | Recruiting | USA | TUR | SWE | POL | NZL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT04123366 | Phase II | Olaparib + Pembrolizumab | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | Active, not recruiting | USA | TUR | SWE | ROU | POL | LVA | ITA | ISR | FRA | ESP | DEU | CAN | AUS | ARG | 9 |
NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Active, not recruiting | USA | TUR | ROU | LTU | ITA | ISR | HUN | GRC | GBR | FRA | EST | ESP | CAN | BGR | BEL | AUS | 9 |
NCT05568550 | Phase II | Pembrolizumab Olaparib + Pembrolizumab | Pembro With Radiation With or Without Olaparib | Recruiting | USA | 0 |
NCT03976362 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | Active, not recruiting | USA | TUR | ROU | POL | NZL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 6 |
NCT05033756 | Phase II | Olaparib + Pembrolizumab | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO) | Active, not recruiting | DEU | 0 |
NCT05201612 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA) | Recruiting | ESP | 0 |
NCT04548752 | Phase II | Olaparib + Pembrolizumab Olaparib | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | Recruiting | USA | 0 |